Blood test aims to balance infection and rejection risks in kidney transplants
NCT ID NCT01424345
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether a blood test called ImmuKnow can help doctors better manage anti-rejection drugs in kidney transplant patients. The goal was to reduce infections while still preventing organ rejection. Only 4 patients were enrolled before the study was stopped early, so the results are very limited.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for END-STAGE RENAL DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CAMC
Charleston, West Virginia, 25301, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug work safely in patients with kidney failure?
- What does life feel like for children with a rare birth defect? a new study asks
- AI therapy coach aims to ease distress in seriously ill seniors
- A simple stretch during dialysis might soothe restless legs
- A regenerative graft could rethink dialysis access
- Pumpkin seed oil may fight inflammation in kidney patients — a trial puts it to the test